Keywords: Novartis, Vectura, NVA237, Seebri Breezhaler, Multiple sclerosis, Gilenya, Ilaris, CAPS, COPD, Europe, Japan
Novartis and Vectura’s NVA237 filed in Europe; positive Ph III data at ERS; Gilenya, Ilaris approved in Japan
Article | 28 September 2011
Shares of UK-based Vectura (LSE: VEC) rose 5.5% to 91 pence by midday yesterday, after the company announces that NVA237 (glycopyrronium bromide), ...
Enjoying this article? To continue reading you need to login or subscribe.
Subscribe now
for unlimited access to all articles
Subscriptions are £60 per month, pay as you go.
Find out more details.
Already a subscriber? Click here to log in
- Encouraging results with Sangamo's SB-728-T in HIV treatment
- Bristol-Myers' data on Yervoy and nivolumab causes a stir
- Boehringer Ingelheim transitions to propellant-free Combivent Respimat; names new BMD member
- Sanofi prepares for regulatory filing of MF candidate on positive JAKARTA study results
- Neovacs moving forward in rheumatoid arthritis, say analysts
